The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 02, 2015

Filed:

Aug. 07, 2008
Applicants:

Elazar Rabbani, NewYork, NY (US);

Xiaofeng LI, Farmington, NY (US);

Dakai Liu, South Setauket, NY (US);

Yazhou Zhang, South Setauket, NY (US);

Richard Jin, Pennington, NJ (US);

Riddhi Bhattacharyya, West Babylon, NY (US);

Wei Cheng, Valley Stream, NY (US);

James J. Donegan, Long Beach, NY (US);

Inventors:

Elazar Rabbani, NewYork, NY (US);

Xiaofeng Li, Farmington, NY (US);

Dakai Liu, South Setauket, NY (US);

Yazhou Zhang, South Setauket, NY (US);

Richard Jin, Pennington, NJ (US);

Riddhi Bhattacharyya, West Babylon, NY (US);

Wei Cheng, Valley Stream, NY (US);

James J. Donegan, Long Beach, NY (US);

Assignee:

Enzo Biochem, Inc., New York, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/00 (2006.01); A61K 31/33 (2006.01); A01N 61/00 (2006.01); A61K 31/00 (2006.01); A61K 31/535 (2006.01); A01N 43/02 (2006.01); A61K 31/335 (2006.01); A01N 43/16 (2006.01); A61K 31/35 (2006.01); G01N 33/92 (2006.01); A61K 31/015 (2006.01); A61K 31/395 (2006.01); G01N 33/50 (2006.01); G01N 33/564 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/92 (2013.01); A61K 31/535 (2013.01); A61K 31/015 (2013.01); A61K 31/395 (2013.01); A61K 38/00 (2013.01); G01N 33/5011 (2013.01); G01N 33/5041 (2013.01); G01N 33/564 (2013.01); G01N 2333/705 (2013.01); G01N 2800/24 (2013.01);
Abstract

The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands.


Find Patent Forward Citations

Loading…